XOMA Reports Fourth Quarter and Full-Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
RBC Capita Affirms XOMA (XOMA) at 'Sector Perform'; Gevokizumab Sale Could Bring in More non-Dilutive Cash
March 10, 2016 7:41 AM ESTRBC Capita affirms XOMA Corporation (Nasdaq: XOMA) with a Sector Perform rating and $2 price target following Q4 results and update issued Wednesday night:
Analyst Adnan Butt commented: Focus now is earlier stage endocrine programs with enough cash at hand through proof of... More
XOMA (XOMA) Tops Q4 Views
March 9, 2016 4:02 PM ESTXOMA (NASDAQ: XOMA) reported Q4 EPS of $0.21, $0.36 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $48.18 million versus the consensus estimate of $4.01 million.
For earnings history and earnings-related data on XOMA (XOMA) click here.
... More